FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
World journal of experimental medicine2017; 7(2); 42-48; doi: 10.5493/wjem.v7.i2.42

Recent clinical trials of cancer immunogene therapy in companion animals.

Abstract: This mini-review presents the results of veterinary clinical trials on immunogene therapy published from 2014 to 2016. A variety of tumors, among them melanoma (canine and equine), mastocytoma (canine), mammary adenocarcinoma (canine) and fibrosarcoma (feline) were treated by using diverse strategies. Non-viral vectors were usually employed to transfer genes of cytokines, suicide enzymes and/or tumor associated antigens. In general terms, minor or no adverse collateral effects were related to these procedures, and treated patients frequently improved their conditions (better quality of life, delayed or suppressed recurrence or metastatic spread, increased survival). Some of these new methodologies have a promising future if applied as adjuvant treatments of standard approaches. The auspicious results, derived from immunogene therapy studies carried out in companion animals, warrant their imperative usage in veterinary clinical oncology. Besides, they provide a strong preclinical basis (safety assays and proofs of concept) for analogous human clinical trials.
Get Full Text
Publication Date: 2017-05-20 PubMed ID: 28589078PubMed Central: PMC5439171DOI: 10.5493/wjem.v7.i2.42Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article reviews veterinary clinical trials conducted between 2014 to 2016 on immunogene therapy for treating different types of tumors in companion animals. Observations indicate that these treatments resulted in little to no adverse side effects, and improved the conditions of the patients, paving the way for promising future applications.

Overview of Veterinary Clinical Trials on Immunogene Therapy

  • The article reviews a series of clinical trials conducted on companion animals between 2014 and 2016. These trials used immunogene therapy to treat a range of tumors including melanoma, mastocytoma, mammary adenocarcinoma, and fibrosarcoma in dogs, horses, and cats.
  • Immunogene therapy utilizes genetic engineering techniques to stimulate the body’s immune response against cancerous cells. In these studies, non-viral vectors were employed to transfer genes of cytokines, suicide enzymes, and tumor-associated antigens, which ultimately help the immune system recognize and kill cancer cells.

Results of the Clinical Trials

  • The results of these therapies were largely positive, with minor or no adverse collateral effects reported.
  • Notably, treated animals often saw an improvement in their conditions, demonstrating a better quality of life, delayed or suppressed recurrence or metastatic spread of the tumor, and increased survival.

Future Implications of the Studies

  • The article discusses the potential future implications of these trials, suggesting that immunogene therapies could serve as effective adjunctive treatments complementing standard approaches in animal cancer treatment.
  • These therapies represent promising advances in veterinary oncology and set a precedent for their application in similar situations in human clinical oncology. The results from these trials provide a strong preclinical basis for safety assessments and proofs of concept for analogous human clinical trials.

The Connection Between Animal and Human Clinical Trials

  • The positive results derived from immunogene therapy studies in companion animals strongly support the imperative for their prospective use in veterinary clinical oncology.
  • Beyond veterinary applications, the findings of these studies also underscore the viability of these therapies for human implementation, lending support to the development of analogous human clinical trials.

Cite This Article

APA
(2017). Recent clinical trials of cancer immunogene therapy in companion animals. World J Exp Med, 7(2), 42-48. https://doi.org/10.5493/wjem.v7.i2.42

Publication

World journal of experimental medicine
ISSN: 2220-315X
NlmUniqueID: 101618808
Country: United States
Language: English
Volume: 7
Issue: 2
Pages: 42-48

Researcher Affiliations

Conflict of Interest Statement

Conflict-of-interest statement: The authors declare that there is no conflict of interests regarding the publication of this paper.

References

This article includes 36 references
  1. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C, Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.. Gene Ther 1996 Dec;3(12):1104-12.
    pubmed: 8986437
  2. Glikin GC, Finocchiaro LM. Clinical trials of immunogene therapy for spontaneous tumors in companion animals.. ScientificWorldJournal 2014;2014:718520.
    pmc: PMC4251357pubmed: 25506617doi: 10.1155/2014/718520google scholar: lookup
  3. Jacob JA. Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies.. JAMA 2016 Apr 19;315(15):1550-2.
    pubmed: 27027696doi: 10.1001/jama.2016.0082google scholar: lookup
  4. Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.. Clin Cancer Res 2016 Sep 1;22(17):4380-90.
    pubmed: 26994144doi: 10.1158/1078-0432.ccr-16-0088google scholar: lookup
  5. Fritz SE, Henson MS, Greengard E, Winter AL, Stuebner KM, Yoon U, Wilk VL, Borgatti A, Augustin LB, Modiano JF, Saltzman DA. A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.. Vet Med Sci 2016 Aug;2(3):179-190.
    pmc: PMC5645873pubmed: 29067193doi: 10.1002/vms3.32google scholar: lookup
  6. Michałowska M, Winiarczyk S, Adaszek Ł, Łopuszyński W, Grądzki Z, Salmons B, Günzburg WH. Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.. PLoS One 2014;9(7):e102061.
    pmc: PMC4100764pubmed: 25028963doi: 10.1371/journal.pone.0102061google scholar: lookup
  7. Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.. Cancer Gene Ther 2012 Dec;19(12):852-61.
    pubmed: 23059870doi: 10.1038/cgt.2012.72google scholar: lookup
  8. Finocchiaro LM, Fondello C, Gil-Cardeza ML, Rossi ÚA, Villaverde MS, Riveros MD, Glikin GC. Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.. Hum Gene Ther 2015 Jun;26(6):367-76.
    pmc: PMC4492668pubmed: 25762364doi: 10.1089/hum.2014.130google scholar: lookup
  9. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions.. Curr Gene Ther 2015;15(1):44-54.
    pmc: PMC4280356pubmed: 25429465doi: 10.2174/1566523214666141127093654google scholar: lookup
  10. Cicchelero L, Denies S, Haers H, Vanderperren K, Stock E, Van Brantegem L, de Rooster H, Sanders NN. Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.. Vet Comp Oncol 2017 Dec;15(4):1187-1205.
    pubmed: 27506827doi: 10.1111/vco.12255google scholar: lookup
  11. Jas D, Soyer C, De Fornel-Thibaud P, Oberli F, Vernes D, Guigal P-M, Poulet H, Devauchelle P. Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials Vaccinol 2015;4:1–8.
  12. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.. J Cell Mol Med 2015 Mar;19(3):664-75.
    pmc: PMC4369822pubmed: 25628149doi: 10.1111/jcmm.12382google scholar: lookup
  13. Cicchelero L, Denies S, Vanderperren K, Stock E, Van Brantegem L, de Rooster H, Sanders NN. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.. Cancer Lett 2017 Aug 1;400:205-218.
    pubmed: 27693635doi: 10.1016/j.canlet.2016.09.015google scholar: lookup
  14. Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, Lampreht Tratar U, Rak M, Tozon N. Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours.. Vet Comp Oncol 2017 Jun;15(2):641-654.
    pubmed: 26840222doi: 10.1111/vco.12208google scholar: lookup
  15. Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.. BMC Vet Res 2015 May 14;11:107.
    pmc: PMC4429833pubmed: 25967290doi: 10.1186/s12917-015-0414-9google scholar: lookup
  16. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.. Am J Vet Res 2011 Dec;72(12):1631-8.
    pubmed: 22126691doi: 10.2460/ajvr.72.12.1631google scholar: lookup
  17. Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.. J Vet Intern Med 2011 Jan-Feb;25(1):94-9.
    pubmed: 21143299doi: 10.1111/j.1939-1676.2010.0627.xgoogle scholar: lookup
  18. Sarbu L, Kitchell BE, Bergman PJ. Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma - a retrospective study.. J Feline Med Surg 2017 Feb;19(2):224-230.
    pubmed: 26685147doi: 10.1177/1098612x15623319google scholar: lookup
  19. McLean JL, Lobetti RG. Use of the melanoma vaccine in 38 dogs: The South African experience.. J S Afr Vet Assoc 2015 Apr 30;86(1):1246.
    pmc: PMC6138178pubmed: 26016668doi: 10.4102/jsava.v86i1.1246google scholar: lookup
  20. Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.. J Vet Med Sci 2016 Jun 1;78(5):845-50.
    pmc: PMC4905841pubmed: 26781703doi: 10.1292/jvms.15-0510google scholar: lookup
  21. Verganti S, Berlato D, Blackwood L, Amores-Fuster I, Polton GA, Elders R, Doyle R, Taylor A, Murphy S. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK.. J Small Anim Pract 2017 Jan;58(1):10-16.
    pubmed: 28094857doi: 10.1111/jsap.12613google scholar: lookup
  22. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A, Latanova A, Shcherbinina V, Shifrin V, Shneider A. Pilot study of p62 DNA vaccine in dogs with mammary tumors.. Oncotarget 2014 Dec 30;5(24):12803-10.
    pmc: PMC4350343pubmed: 25296974doi: 10.18632/oncotarget.2516google scholar: lookup
  23. Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.. Clin Cancer Res 2014 Jul 15;20(14):3753-62.
    pubmed: 24874834doi: 10.1158/1078-0432.ccr-13-3042google scholar: lookup
  24. Piras LA, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.. Vet Comp Oncol 2017 Sep;15(3):996-1013.
    pubmed: 27146852doi: 10.1111/vco.12239google scholar: lookup
  25. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.. PLoS One 2009;4(3):e4972.
    pmc: PMC2659423pubmed: 19330034doi: 10.1371/journal.pone.0004972google scholar: lookup
  26. Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.. Mol Ther 2007 Nov;15(11):2044-50.
    pubmed: 17726460doi: 10.1038/sj.mt.6300290google scholar: lookup
  27. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.. Clin Cancer Res 2010 Aug 1;16(15):4057-65.
    pmc: PMC4241567pubmed: 20647477doi: 10.1158/1078-0432.ccr-10-1093google scholar: lookup
  28. Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.. Cancer 2004 Dec 1;101(11):2557-66.
    pubmed: 15517589doi: 10.1002/cncr.20653google scholar: lookup
  29. Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.. Mol Ther 2008 Dec;16(12):2022-9.
    pmc: PMC3909666pubmed: 18797450doi: 10.1038/mt.2008.196google scholar: lookup
  30. Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.. Gynecol Oncol 2013 Oct;131(1):169-73.
    pubmed: 23863356doi: 10.1016/j.ygyno.2013.07.081google scholar: lookup
  31. Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH, Ullenhag G. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.. Br J Cancer 2016 Apr 12;114(8):872-80.
    pmc: PMC4984796pubmed: 27031851doi: 10.1038/bjc.2016.42google scholar: lookup
  32. Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.. Oncotarget 2017 Aug 8;8(32):53730-53739.
    pmc: PMC5581145pubmed: 28881846doi: 10.18632/oncotarget.16574google scholar: lookup
  33. Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Tötterman TH, von Euler H. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.. J Immunother 2013 Jul-Aug;36(6):350-8.
    pubmed: 23799414doi: 10.1097/cji.0b013e31829d8a1bgoogle scholar: lookup
  34. Brown EL, Ramiya VK, Wright CA, Jerald MM, Via AD, Kuppala VN, Hazell WS, Lawman PD, Lawman MJ. Treatment of Metastatic Equine Melanoma with a Plasmid DNA Vaccine Encoding Streptococcus Pyogenes EMM55 Protein. J Equine Vet Sci 2014;34:704–708.
  35. Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O'Connor CM, Powell DJ Jr, Mason NJ. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.. Mol Ther 2016 Sep;24(9):1602-14.
    pmc: PMC5113111pubmed: 27401141doi: 10.1038/mt.2016.146google scholar: lookup
  36. Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K. Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.. Hum Gene Ther Clin Dev 2017 Jun;28(2):80-86.
    pmc: PMC5510041pubmed: 28335614doi: 10.1089/humc.2017.008google scholar: lookup

Citations

This article has been cited 12 times.
  1. Valdivia G, Alonso-Diez Á, Pérez-Alenza D, Peña L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Front Vet Sci 2021;8:623800.
    doi: 10.3389/fvets.2021.623800pubmed: 33681329google scholar: lookup
  2. LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer 2020 Dec;20(12):727-742.
    doi: 10.1038/s41568-020-0297-3pubmed: 32934365google scholar: lookup
  3. Irac SE, Oksa A, Jackson K, Herndon A, Allavena R, Palmieri C. Cytokine Expression in Canine Lymphoma, Osteosarcoma, Mammary Gland Tumour and Melanoma: Comparative Aspects. Vet Sci 2019 Apr 2;6(2).
    doi: 10.3390/vetsci6020037pubmed: 30987001google scholar: lookup
  4. Almela RM, Ansón A. A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma. Vet Sci 2019 Feb 12;6(1).
    doi: 10.3390/vetsci6010015pubmed: 30759787google scholar: lookup
  5. Moshref M, Tangey B, Gilor C, Papas KK, Williamson P, Loomba-Albrecht L, Sheehy P, Kol A. Concise Review: Canine Diabetes Mellitus as a Translational Model for Innovative Regenerative Medicine Approaches. Stem Cells Transl Med 2019 May;8(5):450-455.
    doi: 10.1002/sctm.18-0163pubmed: 30719867google scholar: lookup
  6. Strauss BE, Silva GRO, de Luna Vieira I, Cerqueira OLD, Del Valle PR, Medrano RFV, Mendonça SA. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics (Sao Paulo) 2018 Sep 6;73(suppl 1):e479s.
    doi: 10.6061/clinics/2018/e479spubmed: 30208166google scholar: lookup
  7. Finocchiaro LME, Spector AIM, Agnetti L, Arbe MF, Glikin GC. Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma. Vet Sci 2018 Aug 3;5(3).
    doi: 10.3390/vetsci5030070pubmed: 30081470google scholar: lookup
  8. Stutzer C, Richards SA, Ferreira M, Baron S, Maritz-Olivier C. Metazoan Parasite Vaccines: Present Status and Future Prospects. Front Cell Infect Microbiol 2018;8:67.
    doi: 10.3389/fcimb.2018.00067pubmed: 29594064google scholar: lookup
  9. Arzi B, Moshaverinia A, Verstraete FJM, Fiani N, Nishimura I. Craniomaxillofacial Disorders and Solutions in Humans and Animals. J Dent Res 2018 Apr;97(4):364-370.
    doi: 10.1177/0022034518758017pubmed: 29481293google scholar: lookup
  10. Agnetti L, Fondello C, Villaverde MS, Glikin GC, Finocchiaro LME. Therapeutic potential of bleomycin plus suicide or interferon-β gene transfer combination for spontaneous feline and canine melanoma. Oncoscience 2017 Nov;4(11-12):199-214.
    doi: 10.18632/oncoscience.387pubmed: 29344558google scholar: lookup
  11. Eguren-Santamaria I, Melero I PhD, Rodríguez I, Ortego I, Armero M, Galvez-Cancino F, López-Janeiro A, De Andrea CE, F Sanmamed M. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. J Immunother Cancer 2025 Oct 29;13(10).
    doi: 10.1136/jitc-2024-011279pubmed: 41161818google scholar: lookup
  12. Glikin GC, Finocchiaro LME. Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024). Vet Sci 2025 Apr 3;12(4).
    doi: 10.3390/vetsci12040329pubmed: 40284831google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.